

Jose de Leon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6107142/publications.pdf>

Version: 2024-02-01

434
papers

16,979
citations

15880

67
h-index

32181

105
g-index

445
all docs

445
docs citations

445
times ranked

12601
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimization of Therapy in Patients with Epilepsy and Psychiatric Comorbidities: Key Points. <i>Current Neuropharmacology</i> , 2023, 21, 1755-1766.	1.4	4
2	Clozapine-associated myocarditis in the World Health Organization's pharmacovigilance database: Focus on reports from various countries. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2022, 15, 238-250.	1.0	31
3	Clozapine-induced myocarditis in Russia: Animal studies but no clinical studies. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2022, 15, 294-295.	1.0	10
4	Valproate, obesity and other causes of clozapine poor metabolism in the context of rapid titration may explain clozapine-induced myocarditis: A re-analysis of a Turkish case series. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2022, 15, 281-286.	1.0	13
5	Association between myocarditis and antipsychotics other than clozapine: a systematic literature review and a pharmacovigilance study using VigiBase. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 65-78.	1.3	18
6	Pharmacokinetic drug interactions with oral haloperidol in adults: dose correction factors from a combined weighted analysis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 135-149.	1.5	3
7	An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 537-540.	1.8	6
8	Precision psychiatry: The complexity of personalizing antipsychotic dosing. <i>European Neuropsychopharmacology</i> , 2022, 58, 80-85.	0.3	8
9	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2022, 55, 73-86.	1.7	107
10	Four cases of myocarditis in US hospitals possibly associated with clozapine poor metabolism and a comparison with prior published cases.. <i>Neuropsychopharmacologia Hungarica</i> , 2022, 24, 29-41.	0.1	4
11	Published population pharmacokinetic models of valproic acid in adult patients: a systematic review and external validation in a Chinese sample of inpatients with bipolar disorder. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 621-635.	1.3	3
12	Screening the European pharmacovigilance database for reports of clozapine-related DRESS syndrome: 47 novel cases. <i>European Neuropsychopharmacology</i> , 2022, 60, 25-37.	0.3	14
13	The history of clozapine in clinical practice: From its introduction to a guideline proposing personalized titrations. <i>Journal of Psychopharmacology</i> , 2022, 36, 657-660.	2.0	9
14	Promoting safer clozapine dosing in the Americas. <i>Revista Brasileira De Psiquiatria</i> , 2022, , .	0.9	2
15	Clozapine and the risk of haematological malignancies. <i>Lancet Psychiatry</i> , 2022, 9, 537-538.	3.7	12
16	An international clozapine titration guideline for clozapine: An opportunity for moving forward on personalizing clozapine treatment in India and other countries. <i>Indian Journal of Psychiatry</i> , 2022, 64, 331.	0.4	2
17	Clozapine for the treatment of pediatric encephalopathy associated with nonketotic hyperglycinemia. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2022, 15, 287-289.	1.0	4
18	A Covid-19 outbreak in a Spanish long-term psychiatric hospital led to infections in 6 clozapine patients: elevations in their plasma clozapine levels. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2022, 15, 290-292.	1.0	11

#	ARTICLE	IF	CITATIONS
19	An international guideline with six personalised titration schedules for preventing myocarditis and pneumonia associated with clozapine. <i>Annals of General Psychiatry</i> , 2022, 35, e100773.	1.1	11
20	Effect of necessityâ€concern framework and polypharmacy on treatment adherence in psychiatric patients. Comparing an Argentinian with a Spanish sample. <i>Human Psychopharmacology</i> , 2021, 36, e2776.	0.7	1
21	Clinimetric Criteria for Patient-Reported Outcome Measures. <i>Psychotherapy and Psychosomatics</i> , 2021, 90, 222-232.	4.0	84
22	An update on the complex relationship between clozapine and pneumonia. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 145-149.	1.3	30
23	European Whites May Need Lower Minimum Therapeutic Clozapine Doses Than Those Customarily Proposed. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 140-147.	0.7	19
24	The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 353-371.	0.6	16
25	A reappraisal of the role of fever in the occurrence of neurological sequelae following lithium intoxication: a systematic review. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 827-838.	1.0	7
26	Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain) <i>Tj ETQqO 0 0 rgBT /Overlock 10 Tf 50 Psychiatry</i> , 2021, 22, 561-628.	1.3	17
27	Reflections on US Psychiatry. <i>Journal of Nervous and Mental Disease</i> , 2021, 209, 403-408.	0.5	2
28	Amerindians may need clozapine dosing similar to that of Asians. <i>Revista De PsiquiatrÃa Y Salud Mental</i> , 2021, 14, 177-179.	1.0	15
29	Amerindians may need clozapine dosing similar to that of Asians. <i>Revista De PsiquiatrÃa Y Salud Mental (English Edition)</i> , 2021, 14, 177-179.	0.2	1
30	Tools for optimizing pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain) <i>Tj ETQqO 0 0 rgBT /Overlock 10 Tf 50 Psychiatry</i> , 2021, 22, 561-628.	0.6	1
31	Poor Adherence to Oral Psychiatric Medication in Adults with Bipolar Disorder: The Psychiatrist May have More Influence than in Other Severe Mental Illnesses.. <i>Neuropsychopharmacologia Hungarica</i> , 2021, 23, 347-362.	0.1	0
32	Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics. <i>Neuropharmacology</i> , 2020, 168, 107656.	2.0	49
33	Rapid Titration and Decreased Clozapine Clearance May Help Explain Five Cases of Clozapine-Induced Myocarditis in a New York Hospital. <i>Psychosomatics</i> , 2020, 61, 102-103.	2.5	23
34	Dose and safety concerns of clozapine: Worldwide package inserts need revisions. <i>Schizophrenia Research</i> , 2020, 216, 2-4.	1.1	16
35	Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other secondâ€cgeneration antipsychotics. <i>World Psychiatry</i> , 2020, 19, 120-121.	4.8	60
36	Data From the World Health Organizationâ€™s Pharmacovigilance Database Supports the Prominent Role of Pneumonia in Mortality Associated With Clozapine Adverse Drug Reactions. <i>Schizophrenia Bulletin</i> , 2020, 46, 1-3.	2.3	75

#	ARTICLE	IF	CITATIONS
37	Clinically relevant drug interactions between newer antidepressants and oral anticoagulants. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 31-44.	1.5	27
38	Future Studies on the Interaction Between Clozapine and Valproic Acid Should Aspire to Include Longitudinal Designs and Free Valproate Concentrations, and Should Consider that Inducer and/or Inhibitory Effects May Vary With Time, the Individual, and the Auto-Induction of Valproic Acid. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 159-161.	1.0	26
39	Antipsychotic medication exposure, clozapine, and pneumonia: results from a self-controlled study. <i>Acta Psychiatrica Scandinavica</i> , 2020, 142, 78-86.	2.2	17
40	<p>Self-Report for Measuring and Predicting Medication Adherence: Expertsâ€™ Experience in Predicting Adherence in Stable Psychiatric Outpatients and in Pharmacokinetics<p>. Patient Preference and Adherence, 2020, Volume 14, 1823-1842.	0.8	7
41	Do Asian Patients Require Only Half of the Clozapine Dose Prescribed for Caucasians? A Critical Overview. <i>Indian Journal of Psychological Medicine</i> , 2020, 42, 4-10.	0.6	61
42	CYP2D6 pharmacogenetics and risperidone: reflections after 25 years of research. <i>Pharmacogenomics</i> , 2020, 21, 1139-1144.	0.6	5
43	Adding Oral Contraceptives to Clozapine May Require Halving the Clozapine Dose. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 308-310.	0.7	16
44	Edentulousness in severely mentally ill patients: A pilot study of sex-specific patterns for risk factors including the glutathione S-transferase M1 gene. <i>Schizophrenia Research</i> , 2020, 224, 178-179.	1.1	0
45	Clinically Relevant Interactions between Atypical Antipsychotics and Anti-Infective Agents. <i>Pharmaceuticals</i> , 2020, 13, 439.	1.7	21
46	Is there a future for <i>CYP1A2</i> pharmacogenetics in the optimal dosing of clozapine?. <i>Pharmacogenomics</i> , 2020, 21, 369-373.	0.6	33
47	Pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-resistant schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2020, 142, 66-67.	2.2	24
48	The association of clozapine and haematological malignancies needs to be replicated by other studies and more importantly by analyses of subsamples from VigiBase. <i>Psychological Medicine</i> , 2020, , 1-2.	2.7	1
49	Clozapine is strongly associated with the risk of pneumonia and inflammation. <i>Annals of General Psychiatry</i> , 2020, 33, e100183.	1.1	50
50	Measuring individual benefits of psychiatric treatment using longitudinal binary outcomes: Application to antipsychotic benefits in non-cannabis and cannabis users. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 916-940.	0.4	3
51	<i>CYP2D6</i> Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis. <i>Pharmacotherapy</i> , 2020, 40, 632-647.	1.2	21
52	Around 3% of 1,300 Levels Were Elevated during Infections in a Retrospective Review of 131 Beijing Hospital In-Patients with More than 24,000 Days of Clozapine Treatment. <i>Psychotherapy and Psychosomatics</i> , 2020, 89, 255-257.	4.0	37
53	Using therapeutic drug monitoring to personalize clozapine dosing in Asians. <i>Asia-Pacific Psychiatry</i> , 2020, 12, e12384.	1.2	29
54	High Doses of Drugs Extensively Metabolized by CYP3A4 Were Needed to Reach Therapeutic Concentrations in Two Patients Taking Inducers. <i>Revista Colombiana De Psiquiatría (English Ed)</i> , 2020, 49, 83-94.	0.1	0

#	ARTICLE	IF	CITATIONS
55	Lack of ECT effects on clozapine plasma levels in patients with treatment-resistant schizophrenia: Pharmacokinetic evidence from a randomized clinical trial. <i>Schizophrenia Research</i> , 2020, 218, 309-311.	1.1	1
56	The necessity of a concern framework in the assessment of treatment adherence of psychiatric patients and the role of polypharmacy in a Spanish sample. <i>Human Psychopharmacology</i> , 2020, 35, e2721.	0.7	3
57	A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology. <i>Psychotherapy and Psychosomatics</i> , 2020, 89, 200-214.	4.0	101
58	High Doses of Drugs Extensively Metabolized by CYP3A4 Were Needed to Reach Therapeutic Concentrations in Two Patients Taking Inducers. <i>Revista Colombiana De Psiquiatría</i> , 2020, 49, 84-95.	0.1	6
59	Catatonia Following Abrupt Cessation of Oxcarbazepine in a Patient With Prader-Willi Syndrome. <i>Psychosomatics</i> , 2019, 60, 311-315.	2.5	4
60	Thirty Years of Both Ignorance and Clinical Experience Suggest That Clozapine Intoxication During Co-Occurring Infections and Inflammation May Have Higher Morbidity and Mortality Than Is Currently Believed. <i>Psychosomatics</i> , 2019, 60, 221-222.	2.5	18
61	Clinical determinants of fever in clozapine users and implications for treatment management: A narrative review. <i>Schizophrenia Research</i> , 2019, 211, 1-9.	1.1	52
62	A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 603-621.	1.3	69
63	Development and validation of the Patient's Health Belief Questionnaire on Psychiatric Treatment. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 527-536.	0.8	12
64	Ethnopsychopharmacology study of patients' beliefs regarding concerns about and necessity of taking psychiatric medications. <i>Human Psychopharmacology</i> , 2019, 34, e2688.	0.7	4
65	ADGRL3 (LPHN3) variants predict substance use disorder. <i>Translational Psychiatry</i> , 2019, 9, 42.	2.4	29
66	Letter to the Editor: Clinical versus statistical significance of pharmacogenomic-guided antidepressant therapy: What's really being measured and marketed?. <i>Journal of Psychiatric Research</i> , 2019, 114, 208-209.	1.5	8
67	Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP2D6) Genotype and Atomoxetine Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 94-102.	2.3	152
68	A comprehensive review of swallowing difficulties and dysphagia associated with antipsychotics in adults. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 219-234.	1.3	53
69	Gemfibrozil May Decrease Norclozapine Elimination. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 405-407.	0.7	10
70	Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder. <i>CNS Drugs</i> , 2019, 33, 1201-1222.	2.7	19
71	Exploring the Prevalence of Clozapine Phenotypic Poor Metabolizers in 4 Asian Samples. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 644-648.	0.7	39
72	Clozapine Metabolism in East Asians and Caucasians. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 135-144.	0.7	58

#	ARTICLE	IF	CITATIONS
73	A Clinimetric Approach for Improving the Measurement of Pharmacophobia with Replication in Two Other Samples. <i>Psychotherapy and Psychosomatics</i> , 2019, 88, 116-118.	4.0	6
74	Studies of Half-Lives of Long-Acting Antipsychotics are Needed. <i>Pharmacopsychiatry</i> , 2019, 52, 45-46.	1.7	5
75	Why Do You Keep Telling Me That Drug-Drug Interactions Are Important in Psychopharmacology When I Do Not See Them in My Clinical Practice?. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 1-4.	0.7	18
76	Quantitative determination of risperidone, paliperidone and olanzapine in human serum by liquid chromatography-tandem mass spectrometry coupled with on-line solid-phase extraction. <i>Biomedical Chromatography</i> , 2018, 32, e4209.	0.8	11
77	Further evidence for major repeaters as a subgroup of suicide attempters. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2018, 11, 60-61.	0.2	1
78	Predictive validity of the Sidorkiewicz instrument in Spanish: Assessing individual drug adherence in psychiatric patients. <i>International Journal of Clinical and Health Psychology</i> , 2018, 18, 133-142.	2.7	12
79	Two cases of high serum clozapine concentrations occurring during inflammation in Chinese patients. <i>International Journal of Psychiatry in Medicine</i> , 2018, 53, 292-305.	0.8	20
80	Cannabinoid Receptors, Mental Pain and Suicidal Behavior: a Systematic Review. <i>Current Psychiatry Reports</i> , 2018, 20, 19.	2.1	11
81	Possible Pharmacodynamic and Pharmacokinetic Drug-Drug Interactions That Are Likely to Be Clinically Relevant and/or Frequent in Bipolar Disorder. <i>Current Psychiatry Reports</i> , 2018, 20, 17.	2.1	31
82	Possible Oxcarbazepine Inductive Effects on Aripiprazole Metabolism: A Case Report. <i>Journal of Pharmacy Practice</i> , 2018, 31, 361-363.	0.5	11
83	M�as evidencias de que los grandes repetidores se comportan como un subgrupo en la conducta suicida. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2018, 11, 60-61.	1.0	5
84	A Critical Commentary on the 2017 AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology. <i>Pharmacopsychiatry</i> , 2018, 51, 63-68.	1.7	19
85	Pharmacokinetics of risperidone in different application forms – Comparing long-acting injectable and oral formulations. <i>European Neuropsychopharmacology</i> , 2018, 28, 130-137.	0.3	22
86	A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 1237-1253.	1.3	37
87	The Effect of Body Weight Changes on Total Plasma Clozapine Concentrations Determined by Applying a Statistical Model to the Data From a Double-Blind Trial. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 442-446.	0.7	37
88	A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 625-639.	1.3	34
89	Prolactin levels: sex differences in the effects of risperidone, 9-hydroxyrisperidone levels, <i>CYP2D6</i> and <i>ABCB1</i> variants. <i>Pharmacogenomics</i> , 2018, 19, 815-823.	0.6	7
90	Skepticism and pharmacophobia toward medication may negatively impact adherence to psychiatric medications: a comparison among outpatient samples recruited in Spain, Argentina, and Venezuela. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 301-310.	0.8	18

#	ARTICLE	IF	CITATIONS
91	Periodic Catatonia Marked by Hypercortisolemia and Exacerbated by the Menses: A Case Report and Literature Review. <i>Case Reports in Psychiatry</i> , 2018, 2018, 1-12.	0.2	3
92	Potentially Clinically Relevant Pharmacodynamic Interactions Between Antiepileptic Drugs and Psychotropic Drugs: An Update. <i>Current Pharmaceutical Design</i> , 2018, 23, 5625-5638.	0.9	13
93	Unexpected Falls During Clozapine Treatment Explained by Myoclonus. primary care companion for CNS disorders, <i>The</i> , 2018, 20, .	0.2	7
94	Young Researchers and Young Clinicians Should Not Pay Much Attention to the Journal Impact Factor When Selecting a Journal for Publishing Articles. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 86-87.	0.7	1
95	Rapid Development of Lorazepam Tolerance Within 48 Hours in an Adult With Intellectual Disability Who Presented With Stuporous Catatonia and Refused Electroconvulsive Therapy. primary care companion for CNS disorders, <i>The</i> , 2018, 20, .	0.2	2
96	Teaching Medical Students How To Think: Narrative, Mechanistic and Mathematical Thinking. <i>Actas Espanolas De Psiquiatria</i> , 2018, 46, 133-45.	0.1	3
97	Reviving Research on Medication Attitudes for Improving Pharmacotherapy: Focusing on Adherence. <i>Psychotherapy and Psychosomatics</i> , 2017, 86, 73-79.	4.0	36
98	Pneumonia Can Cause Clozapine Intoxication: A Case Report. <i>Psychosomatics</i> , 2017, 58, 652-656.	2.5	23
99	The Art of Pharmacotherapy. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 131-137.	0.7	19
100	Have we successfully implemented CYP2D6 genotyping in psychiatry?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1201-1203.	1.5	4
101	A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 965-981.	1.3	69
102	Catatonia Secondary to Sudden Clozapine Withdrawal: A Case with Three Repeated Episodes and a Literature Review. <i>Case Reports in Psychiatry</i> , 2017, 2017, 1-11.	0.2	25
103	Factors influencing adherence to psychopharmacological medications in psychiatric patients: a structural equation modeling approach. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 681-690.	0.8	35
104	Pulmonary Embolism during Stuporous Episodes of Catatonia Was Found to Be the Most Frequent Cause of Preventable Death According to a State Mortality Review: 6 Deaths in 15 Years. <i>Clinical Schizophrenia and Related Psychoses</i> , 2017, , .	1.4	5
105	Clozapine Augmentation With Antiepileptic Drugs for Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e498-e505.	1.1	46
106	Moria. primary care companion for CNS disorders, <i>The</i> , 2017, 19, .	0.2	1
107	Two Sudden and Unexpected Deaths of Patients with Schizophrenia Associated with Intramuscular Injections of Antipsychotics and Practice Guidelines to Limit the Use of High Doses of Intramuscular Antipsychotics. <i>Case Reports in Psychiatry</i> , 2016, 2016, 1-14.	0.2	10
108	The Addictive Model of Self-Harming (Non-suicidal and Suicidal) Behavior. <i>Frontiers in Psychiatry</i> , 2016, 7, 8.	1.3	99

#	ARTICLE	IF	CITATIONS
109	Pathophysiology and clinical trials have limitations in some areas of medicine: focus on psychiatry (letter commenting: J Clin Epidemiol. 2014;67(4):361-363.). Journal of Clinical Epidemiology, 2016, 75, 126-127.	2.4	2
110	Patterns of Comorbidity of Suicide Attempters: An Update. Current Psychiatry Reports, 2016, 18, 93.	2.1	15
111	What is needed to incorporate clinical pharmacogenetic tests into the practice of psychopharmacotherapy?. Expert Review of Clinical Pharmacology, 2016, 9, 351-354.	1.3	15
112	CYP2D6 ultra-rapid metabolizer phenotype not associated with attempted suicide in a large sample of psychiatric inpatients. Pharmacogenomics, 2016, 17, 1295-1304.	0.6	0
113	Ibuprofen May Increase Pharmacological Action of Valproate by Displacing It From Plasma Proteins: A Case Report. American Journal of Psychiatry, 2016, 173, 941-942.	4.0	10
114	Reply to the Multifaceted Aspects of Suicide Behavior by Tondo. Psychotherapy and Psychosomatics, 2016, 85, 112-113.	4.0	2
115	Pharmacogenetic Tests in Psychiatry. Journal of Clinical Psychopharmacology, 2016, 36, 299-304.	0.7	30
116	Adjunctive metformin for antipsychotic-induced hyperprolactinemia: A systematic review. Psychiatry Research, 2016, 237, 257-263.	1.7	36
117	Beyond the corrupting influence of pharmaceutical companies on antidepressant meta-analyses (Letter commenting on: J Clin Epidemiol. 70, 2016, 155-163). Journal of Clinical Epidemiology, 2016, 78, 127-128.	2.4	0
118	Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 407-422.	1.5	82
119	Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Pharmacological Research, 2016, 106, 72-86.	3.1	85
120	Single- and Multiple-Dose Milnacipran Pharmacokinetics in Healthy Han Chinese Volunteers. Clinical Pharmacokinetics, 2016, 55, 889-896.	1.6	3
121	Clozapine-induced myocarditis may be associated with rapid titration. International Journal of Psychiatry in Medicine, 2016, 51, 104-115.	0.8	41
122	APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer's disease. Molecular Psychiatry, 2016, 21, 916-924.	4.1	89
123	Reduction in serum concentration of valproic acid secondary to the intake of ibuprofen as an example of valproic acid auto-induction metabolism. Actas Espanolas De Psiquiatria, 2016, 44, 136-44.	0.1	12
124	A Case Report That Suggested That the Patient Was Very Sensitive to Induction and Needed 1600 mg/d of Lamotrigine to Get Therapeutic Concentrations. Journal of Clinical Psychopharmacology, 2015, 35, 745-747.	0.7	8
125	A combined analysis of worldwide studies demonstrates an association between bipolar disorder and tobacco smoking behaviors in adults. Bipolar Disorders, 2015, 17, 575-597.	1.1	81
126	Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment. Journal of Clinical Psychopharmacology, 2015, 35, 499-509.	0.7	70

#	ARTICLE	IF	CITATIONS
127	Titrating clozapine amidst recommendations proposing high myocarditis risk and rapid titrations. <i>Acta Psychiatrica Scandinavica</i> , 2015, 132, 242-243.	2.2	32
128	Catatonia in Older Adult Individuals with Intellectual Disabilities. <i>Case Reports in Psychiatry</i> , 2015, 2015, 1-9.	0.2	5
129	Three Patients Needing High Doses of Valproic Acid to Get Therapeutic Concentrations. <i>Case Reports in Psychiatry</i> , 2015, 2015, 1-12.	0.2	16
130	Caffeine consumption in a long-term psychiatric hospital: Tobacco smoking may explain in large part the apparent association between schizophrenia and caffeine use. <i>Schizophrenia Research</i> , 2015, 164, 234-241.	1.1	20
131	Horror Vacui: Emptiness Might Distinguish between Major Suicide Repeaters and Nonmajor Suicide Repeaters: A Pilot Study. <i>Psychotherapy and Psychosomatics</i> , 2015, 84, 117-119.	4.0	32
132	From the Serotonin Model of Suicide to a Mental Pain Model of Suicide. <i>Psychotherapy and Psychosomatics</i> , 2015, 84, 323-329.	4.0	38
133	The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: A summary of the current state for clinicians. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2015, 8, 97-115.	0.2	8
134	Translating Pharmacogenetics to Clinical Practice: Do Cytochrome P450 2D6 Ultrarapid Metabolizers Need Higher Atomoxetine Doses?. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 532-534.	0.3	13
135	Is psychiatry only neurology? Or only abnormal psychology? Dã©jã vu after 100 years. <i>Acta Neuropsychiatrica</i> , 2015, 27, 69-81.	1.0	20
136	Efectos de los inductores antiepilã©pticos en la neuropsicofarmacologã©a: una cuestiã©n ignorada. Parte I: Resumen para los clã©nicos de la situaciã©n actual. <i>Revista De Psiquiatría Y Salud Mental</i> , 2015, 8, 97-115.	1.0	29
137	Phenoconversion and therapeutic drug monitoring. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 777-778.	1.1	18
138	Efectos de los inductores antiepilã©pticos en la neuropsicofarmacologã©a: una cuestiã©n ignorada. Parte II: cuestiones farmacolã©gicas y compresiã©n adicional. <i>Revista De Psiquiatría Y Salud Mental</i> , 2015, 8, 167-188.	1.0	29
139	The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part II: Pharmacological issues and further understanding. <i>Revista De Psiquiatría Y Salud Mental (English)</i> Tj ETQq1 1 0.784214 rgB5 /Overlo	1.1	18
140	Clinical applications of CYP genotyping in psychiatry. <i>Journal of Neural Transmission</i> , 2015, 122, 5-28.	1.4	122
141	Clozapine for treatment-resistant bipolar disorder: a systematic review. <i>Bipolar Disorders</i> , 2015, 17, 235-247.	1.1	105
142	Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 721-746.	1.5	93
143	Can Valproic Acid be an Inducer of Clozapine Metabolism?. <i>Pharmacopsychiatry</i> , 2014, 47, 89-96.	1.7	50
144	The Old and the New Eastern State Hospital in Lexington, Kentucky. <i>American Journal of Psychiatry</i> , 2014, 171, 149-150.	4.0	0

#	ARTICLE	IF	CITATIONS
145	Response to Gorelick. American Journal of Psychiatry, 2014, 171, 691-692.	4.0	3
146	A postâ€‹i> <scp>DSM</scp>â€‹scp>III</scp></i> wakeâ€‹up call to <scp>E</scp>uropean psychiatry. Acta Psychiatrica Scandinavica, 2014, 129, 76-77.	2.2	6
147	Is it time to awaken Sleeping Beauty? European psychiatry has been sleeping since 1980. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2014, 7, 186-194.	0.2	3
148	False-Negative Studies May Systematically Contaminate the Literature on the Effects of Inducers in Neuropsychopharmacology. Part I. Journal of Clinical Psychopharmacology, 2014, 34, 177-183.	0.7	17
149	Paradoxes of US Psychopharmacology Practice in 2013. Journal of Clinical Psychopharmacology, 2014, 34, 545-548.	0.7	8
150	False-Negative Studies May Systematically Contaminate the Literature on the Effects of Inducers in Neuropsychopharmacology. Journal of Clinical Psychopharmacology, 2014, 34, 291-296.	0.7	21
151	One Hundred Years of Limited Impact of Jaspersâ€™™ General Psychopathology on US Psychiatry. Journal of Nervous and Mental Disease, 2014, 202, 79-87.	0.5	12
152	Focusing on drug versus disease mechanisms and on clinical subgrouping to advance personalised medicine in psychiatry. Acta Neuropsychiatrica, 2014, 26, 327-333.	1.0	12
153	DSM-5 and the Research Domain Criteria: 100 Years After Jaspersâ€™™<i>General Psychopathology</i>. American Journal of Psychiatry, 2014, 171, 492-494.	4.0	14
154	Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. Psychological Medicine, 2014, 44, 37-50.	2.7	37
155	Management of suicidal behaviour: Is the world upside down?. Australian and New Zealand Journal of Psychiatry, 2014, 48, 399-401.	1.3	12
156	QT Interval Prolongation Associated with Intramuscular Ziprasidone in Chinese Patients: A Case Report and a Comprehensive Literature Review with Meta-Analysis. Case Reports in Psychiatry, 2014, 2014, 1-8.	0.2	8
157	Pharmacogenomics in Psychiatry: From Therapeutic Drug Monitoring to Genomic Medicine. Clinical Pharmacology and Therapeutics, 2014, 95, 254-257.	2.3	56
158	Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1457-1489.	1.5	47
159	Â¿Es cientÃfica la psiquiatrÃa? Carta al residente de psiquiatrÃa del siglo xxi. Psiquiatria Biologica, 2014, 21, 14-24.	0.0	0
160	Â¿Es hora de despertar a la Bella Durmiente? En 1980, la psiquiatrÃa europea cayÃ³ en un profundo sueÃ±o. Revista De PsiquiatrÃa Y Salud Mental, 2014, 7, 186-194.	1.0	10
161	Â¿EstÃn los grandes repetidores adictos a los comportamientos suicidas?. Revista De Psicología De La Salud, 2014, 26, 321.	0.2	22
162	A Cross-Sectional Study of Major Repeaters. primary care companion for CNS disorders, The, 2014, 16, .	0.2	18

#	ARTICLE	IF	CITATIONS
163	Personality disorders and health problems distinguish suicide attempters from completers in a direct comparison. <i>Journal of Affective Disorders</i> , 2013, 151, 474-483.	2.0	60
164	The Lions of Granada Maristan. <i>American Journal of Psychiatry</i> , 2013, 170, 152-153.	4.0	18
165	A Case Report That Suggested That Aspirin's Effects on Valproic Acid Metabolism May Contribute to Valproic Acid's Inducer Effects on Clozapine Metabolism. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 812-814.	0.7	32
166	Clobazam Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 30-47.	1.0	67
167	The Mathematics of Drug Dose Individualization Should Be Built With Random-Effects Linear Models. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 276-277.	1.0	15
168	Is Psychiatry Scientific? A Letter to a 21st Century Psychiatry Resident. <i>Psychiatry Investigation</i> , 2013, 10, 205.	0.7	33
169	A Practitioner's Guide to Prescribing Diazepam for Adults with Intellectual Disabilities. , 2012, , 75-94.		0
170	Evidence-Based Medicine Versus Personalized Medicine. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 153-164.	0.7	70
171	Drug Dosage Individualization Based on a Random-Effects Linear Model. <i>Journal of Biopharmaceutical Statistics</i> , 2012, 22, 463-484.	0.4	20
172	Worldwide impact of economic cycles on suicide trends over 3â€¦decades: differences according to level of development. A mixed effect model study. <i>BMJ Open</i> , 2012, 2, e000785.	0.8	45
173	Serum IgG Antibodies Against the NR₁ Subunit of the NMDA Receptor Not Detected in Schizophrenia. <i>American Journal of Psychiatry</i> , 2012, 169, 1120-1121.	4.0	93
174	New insights on the consequences of biotransformation processes on the distribution and pharmacodynamic profiles of some neuropsychotropic drugs. <i>European Neuropsychopharmacology</i> , 2012, 22, 319-329.	0.3	8
175	Can the Holmes-Rahe Social Readjustment Rating Scale (SRRS) Be Used as a Suicide Risk Scale? An Exploratory Study. <i>Archives of Suicide Research</i> , 2012, 16, 13-28.	1.2	35
176	Psychosis and smoking cessation: Difficulties in quitting associated with sex and substance abuse. <i>Psychiatry Research</i> , 2012, 195, 45-50.	1.7	10
177	Lower Gastrointestinal Bleeding and Paroxetine Use: Two Case Reports. <i>Psychosomatics</i> , 2012, 53, 184-187.	2.5	8
178	Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 36, 213-219.	2.5	3
179	Relaxin polymorphisms associated with metabolic disturbance in patients treated with antipsychotics. <i>Journal of Psychopharmacology</i> , 2012, 26, 374-379.	2.0	38
180	Role of Statistical Random-Effects Linear Models in Personalized Medicine. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2012, 10, 22-32.	0.2	33

#	ARTICLE	IF	CITATIONS
181	Interactions between antiepileptics and second-generation antipsychotics. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 311-334.	1.5	64
182	A Practitionerâ€™s Guide to Prescribing Phenobarbital for Adults with Intellectual Disabilities. , 2012, , 279-301.		0
183	Genetics of schizophrenia and smoking: an approach to studying their comorbidity based on epidemiological findings. Human Genetics, 2012, 131, 877-901.	1.8	34
184	A Practitionerâ€™s Guide to Prescribing Primidone for Adults with Intellectual Disabilities. , 2012, , 349-365.		0
185	A Practitionerâ€™s Guide to Prescribing Oxcarbazepine for Adults with Intellectual Disabilities. , 2012, , 255-277.		0
186	A Practitionerâ€™s Guide to Prescribing Clonazepam for Adults with Intellectual Disabilities. , 2012, , 55-74.		1
187	A Practitionerâ€™s Guide to Prescribing Lamotrigine for Adults with Intellectual Disabilities. , 2012, , 155-184.		0
188	A Practitionerâ€™s Guide to Prescribing Lorazepam for Adults with Intellectual Disabilities. , 2012, , 235-254.		0
189	A Practitionerâ€™s Guide to Prescribing Phenytoin for Adults with Intellectual Disabilities. , 2012, , 303-332.		0
190	A Practitionerâ€™s Guide to Prescribing Valproate for Adults with Intellectual Disabilities. , 2012, , 419-460.		0
191	A Practitionerâ€™s Guide to Prescribing Rufinamide for Adults with Intellectual Disabilities. , 2012, , 367-380.		0
192	A Practitionerâ€™s Guide to Prescribing Felbamate for Adults with Intellectual Disabilities. , 2012, , 107-122.		0
193	A Practitionerâ€™s Guide to Prescribing Carbamazepine for Adults with Intellectual Disabilities. , 2012, , 19-54.		0
194	Using structural equations to test for a direct effect of some antipsychotics on triglyceride levels in drug-naïve first-episode psychosis patients. Schizophrenia Research, 2011, 131, 82-89.	1.1	7
195	Highlights of Drug Package Inserts and the Website DailyMed. Journal of Clinical Psychopharmacology, 2011, 31, 263-265.	0.7	32
196	Short self-reported sleep duration and suicidal behavior: A cross-sectional study. Journal of Affective Disorders, 2011, 133, 239-246.	2.0	44
197	Lack of Association between Testosterone and Suicide Attempts. Neuropsychobiology, 2011, 63, 125-130.	0.9	30
198	Paying Attention to Pharmacokinetic and Pharmacodynamic Mechanisms to Progress in the Area of Anticholinergic Use in Geriatric Patients. Current Drug Metabolism, 2011, 12, 635-646.	0.7	32

#	ARTICLE	IF	CITATIONS
199	Lack of replication of the association of low serum cholesterol and attempted suicide in another country raises more questions. <i>Annals of Clinical Psychiatry</i> , 2011, 23, 163-70.	0.6	24
200	Nucleotide variation in central nervous system genes among male suicide attempters. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 208-213.	1.1	13
201	Suicide attempts among women during low estradiol/low progesterone states. <i>Journal of Psychiatric Research</i> , 2010, 44, 209-214.	1.5	62
202	Future of Personalized Prescription in Psychiatry. <i>Advances in Biological Psychiatry</i> , 2010, , 118-134.	0.2	1
203	An Exploratory Study of the Relationship between Diverse Life Events and Specific Personality Disorders in a Sample of Suicide Attempters. <i>Journal of Personality Disorders</i> , 2010, 24, 773-784.	0.8	53
204	QTc interval in a sample of long-term schizophrenia inpatients. <i>Schizophrenia Research</i> , 2010, 116, 35-43.	1.1	38
205	Do atypical antipsychotic drugs reduce the risk of ischemic heart disease and mortality? Possible role of 5-HT _{2A} receptor blockade. <i>Schizophrenia Research</i> , 2010, 119, 160-163.	1.1	13
206	Possible effects of some antipsychotic drugs on C-reactive protein in a drug-naïve psychotic sample. <i>Schizophrenia Research</i> , 2010, 121, 207-212.	1.1	37
207	Reply to Lian et al.. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 1159.	2.5	0
208	The Pharmacokinetics of Paliperidone Versus Risperidone. <i>Psychosomatics</i> , 2010, 51, 80-88.	2.5	87
209	The Pharmacokinetics of Paliperidone Versus Risperidone. <i>Psychosomatics</i> , 2010, 51, 80-88.	2.5	99
210	Pharmacokinetic Drug-Drug Interactions Between Olanzapine and Valproate Need to Be Better Studied. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 957-958.	1.1	14
211	Pharmacogenomics: The Promise of Personalized Medicine for CNS Disorders. <i>Neuropsychopharmacology</i> , 2009, 34, 159-172.	2.8	77
212	Fagerstrom test for nicotine dependence vs heavy smoking index in a general population survey. <i>BMC Public Health</i> , 2009, 9, 493.	1.2	87
213	Nicotine exposure can be detected in cerebrospinal fluid of active and passive smokers. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2009, 49, 129-132.	1.4	16
214	Severity of personality disorders and suicide attempt. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 149-155.	2.2	59
215	Tobacco smoking behaviors in bipolar disorder: a comparison of the general population, schizophrenia, and major depression. <i>Bipolar Disorders</i> , 2009, 11, 154-165.	1.1	153
216	The french attempt to include the bouffée délirante in the DSM-IV during 2006: A recollection in the year 2050. <i>L'Encephale</i> , 2009, 35, 1-3.	0.3	6

#	ARTICLE	IF	CITATIONS
217	Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities. <i>Research in Developmental Disabilities</i> , 2009, 30, 613-669.	1.2	61
218	Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 1496-1501.	2.5	38
219	The future (or lack of future) of personalized prescription in psychiatry. <i>Pharmacological Research</i> , 2009, 59, 81-89.	3.1	80
220	Acetyl-coenzyme A carboxylase β gene variations may be associated with the direct effects of some antipsychotics on triglyceride levels. <i>Schizophrenia Research</i> , 2009, 115, 136-140.	1.1	16
221	Implicaciones clínicas de la edad de inicio del trastorno bipolar I: dos subgrupos con diferente pronóstico. <i>Revista De Psiquiatría Y Salud Mental</i> , 2009, 2, 29-34.	1.0	6
222	Age at onset in bipolar I disorder: two may be better than three subgroups. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2009, 2, 29-34.	0.2	2
223	Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients. <i>European Psychiatry</i> , 2009, 24, 456-463.	0.1	21
224	CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for effectiveness studies. <i>Pharmacogenomics</i> , 2009, 10, 685-699.	0.6	34
225	Eosinophilic Pleural Effusion Associated With the Addition of Sodium Valproate. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 310-311.	0.7	15
226	Pharmacokinetic Drug Interaction Studies Must Consider Pharmacological Heterogeneity, Use of Repeated Dosing, and Translation Into a Message Understandable to Practicing Clinicians. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 201-205.	0.7	20
227	Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. <i>Psychiatric Genetics</i> , 2009, 19, 305-311.	0.6	28
228	Valproic Acid Toxicity Associated With Low Dose of Aspirin and Low Total Valproic Acid Levels. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 509-511.	0.7	11
229	DNA Microarray Technology in the Clinical Environment: The AmpliChip CYP450 Test for CYP2D6 and CYP2C19 Genotyping. <i>CNS Spectrums</i> , 2009, 14, 19-35.	0.7	84
230	Effect of Valproate on Olanzapine Plasma Concentrations in Patients With Bipolar or Schizoaffective Disorder. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 758-763.	1.0	40
231	How Should Research Productivity Be Assessed in Early Career Psychiatric Researchers?. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1327-1328.	1.1	0
232	An investigation of the β 1A adrenergic receptor gene and antipsychotic-induced side effects. <i>Human Psychopharmacology</i> , 2008, 23, 107-114.	0.7	22
233	Association study of two polymorphisms of the serotonin $2A$ receptor gene and suicide attempts. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 645-649.	1.1	27
234	CYP2D6 genotyping and codeine. <i>Paediatric Anaesthesia</i> , 2008, 18, 274-275.	0.6	8

#	ARTICLE	IF	CITATIONS
235	Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. <i>Schizophrenia Research</i> , 2008, 98, 40-46.	1.1	37
236	The association between schizophrenia and smoking: Unexplained by either the illness or the prodromal period. <i>Schizophrenia Research</i> , 2008, 104, 214-219.	1.1	30
237	Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1453-1458.	2.5	45
238	S.28.04 Pharmacogenetics of mood stabiliser in bipolar disorder. <i>European Neuropsychopharmacology</i> , 2008, 18, S197.	0.3	1
239	Pharmacogenetic Testing in Psychiatry: A Review of Features and Clinical Realities. <i>Clinics in Laboratory Medicine</i> , 2008, 28, 599-617.	0.7	69
240	A Preliminary Attempt to Personalize Risperidone Dosing Using Drug-Drug Interactions and Genetics: Part I. <i>Psychosomatics</i> , 2008, 49, 258-270.	2.5	37
241	A Preliminary Attempt to Personalize Risperidone Dosing Using Drug-Drug Interactions and Genetics: Part II. <i>Psychosomatics</i> , 2008, 49, 347-361.	2.5	40
242	Metabolic Syndrome and Psychiatric Illness: Interactions, Pathophysiology, Assessment, and Treatment by Scott D. Mendelson, M.D., Ph.D. Burlington, Mass, Academic Press, 2008, 224 pp., \$99.95.. <i>American Journal of Psychiatry</i> , 2008, 165, 1056-1057.	4.0	3
243	Estimating the Size of the Effects of Co-Medications on Plasma Clozapine Concentrations using a Model that Controls for Clozapine Doses and Confounding Variables. <i>Pharmacopsychiatry</i> , 2008, 41, 81-91.	1.7	91
244	The Potential of Genotyping. <i>Science</i> , 2008, 321, 769-769.	6.0	13
245	Paradoxical Excitation on Diphenhydramine May Be Associated with Being a CYP2D6 Ultrarapid Metabolizer: <i>Three Case Reports</i> . <i>CNS Spectrums</i> , 2008, 13, 133-135.	0.7	28
246	Beyond the "Hype" on the Association Between Metabolic Syndrome and Atypical Antipsychotics. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 125-131.	0.7	22
247	Low Serum Cholesterol May Be Associated With Suicide Attempt History. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1920-1927.	1.1	36
248	Smoking Cessation in Patients With Psychiatric Disorders. Primary Care Companion To the Journal of Clinical Psychiatry, 2008, 10, 52-58.	0.6	16
249	Association between smoking and alcohol use in the general population: stable and unstable odds ratios across two years in two different countries. <i>Alcohol and Alcoholism</i> , 2007, 42, 252-257.	0.9	80
250	A Study of Genetic (CYP2D6 and ABCB1) and Environmental (Drug Inhibitors and Inducers) Variables That May Influence Plasma Risperidone Levels. <i>Pharmacopsychiatry</i> , 2007, 40, 93-102.	1.7	101
251	Weight Gain During a Double-Blind Multidosage Clozapine Study. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 22-27.	0.7	56
252	The Crucial Role of the Therapeutic Window in Understanding the Clinical Relevance of the Poor Versus the Ultrarapid Metabolizer Phenotypes in Subjects Taking Drugs Metabolized by CYP2D6 or CYP2C19. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 241-245.	0.7	58

#	ARTICLE	IF	CITATIONS
253	A Case Report With Ziprasidone-Induced Catatonic Symptoms. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2007, 19, 476-477.	0.9	7
254	Epidemiology of Comorbid Tobacco Use and Schizophrenia: Thinking About Risks and Protective Factors. <i>Journal of Dual Diagnosis</i> , 2007, 3, 9-25.	0.7	15
255	Low plasma cholesterol levels in suicidal males: A gender- and body mass index-matched case-control study of suicide attempters and nonattempters. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 901-905.	2.5	51
256	Variables associated with familial suicide attempts in a sample of suicide attempters. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 1312-1316.	2.5	29
257	Subjective effects and the main reason for smoking in outpatients with schizophrenia: a case-control study. <i>Comprehensive Psychiatry</i> , 2007, 48, 186-191.	1.5	31
258	A clinical study of the association of antipsychotics with hyperlipidemia. <i>Schizophrenia Research</i> , 2007, 92, 95-102.	1.1	72
259	Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: The clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy. <i>Schizophrenia Research</i> , 2007, 96, 185-197.	1.1	34
260	No association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and schizophrenia in a Spanish sample. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 344-346.	1.1	11
261	Individualizing drug dosage by using a random intercept linear model. <i>Statistics in Medicine</i> , 2007, 26, 2052-2073.	0.8	31
262	Psychosocial stressors may be strongly associated with suicide attempts. <i>Stress and Health</i> , 2007, 23, 191-198.	1.4	49
263	Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. <i>Molecular Psychiatry</i> , 2007, 12, 474-482.	4.1	59
264	Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. <i>Molecular Psychiatry</i> , 2007, 12, 707-747.	4.1	331
265	Two case reports of oral ulcers with lamotrigine several weeks after oxcarbazepine withdrawal. <i>Bipolar Disorders</i> , 2007, 9, 310-313.	1.1	14
266	Diagnostic stability and evolution of bipolar disorder in clinical practice: a prospective cohort study. <i>Acta Psychiatrica Scandinavica</i> , 2007, 115, 473-480.	2.2	45
267	Metabolic Drug Interactions with Newer Antipsychotics: A Comparative Review. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2007, 100, 4-22.	1.2	223
268	The effect of atypical versus typical antipsychotics on tardive dyskinesia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 257, 169-172.	1.8	43
269	An HPLC method for the simultaneous determination of neurotoxic dipyrindyl isomers in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2007, 45, 120-124.	1.4	0
270	Smoking Cessation in Patients With Psychiatric Disorders. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1404-1410.	1.1	9

#	ARTICLE	IF	CITATIONS
271	The AmpliChip [®] , [†] CYP450 Genotyping Test. <i>Molecular Diagnosis and Therapy</i> , 2006, 10, 135-151.	1.6	178
272	Clinical Guidelines for Psychiatrists for the Use of Pharmacogenetic Testing for CYP450 2D6 and CYP450 2C19. <i>Psychosomatics</i> , 2006, 47, 75-85.	2.5	270
273	AmpliChip CYP450 Test: personalized medicine has arrived in psychiatry. <i>Expert Review of Molecular Diagnostics</i> , 2006, 6, 277-286.	1.5	99
274	Smoking is associated with schizophrenia, but not with mood disorders, within a population with low smoking rates: A matched case-control study in Bucaramanga, Colombia. <i>Schizophrenia Research</i> , 2006, 83, 269-276.	1.1	26
275	Fewer but heavier caffeine consumers in schizophrenia: A case-control study. <i>Schizophrenia Research</i> , 2006, 86, 276-283.	1.1	29
276	Does smoking reduce akathisia? Testing a narrow version of the self-medication hypothesis. <i>Schizophrenia Research</i> , 2006, 86, 256-268.	1.1	33
277	Guidelines for the use of clozapine in individuals with developmental disabilities. <i>Research in Developmental Disabilities</i> , 2006, 27, 309-336.	1.2	38
278	Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006, 30, 1356-1358.	2.5	94
279	Association between the T102C polymorphism of the serotonin-2A receptor gene and schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006, 30, 1136-1138.	2.5	20
280	Datapoints: Smoking and Smoking Cessation Among Persons With Severe Mental Illnesses. <i>Psychiatric Services</i> , 2006, 57, 462-462.	1.1	30
281	A Poor Metabolizer for Cytochromes P450 2D6 and 2C19: <i>A Case Report on Antidepressant Treatment</i>. <i>CNS Spectrums</i> , 2006, 11, 757-760.	0.7	25
282	CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing. <i>Pharmacogenomics Journal</i> , 2006, 6, 343-350.	0.9	84
283	Probable Association Between Ziprasidone and Worsening Hypertension. <i>Pharmacotherapy</i> , 2006, 26, 1352-1357.	1.2	11
284	A Pilot Study on Differences in Aggression in New York City and Madrid, Spain, and Their Possible Impact on Suicidal Behavior. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 375-380.	1.1	35
285	Using Data Mining to Explore Complex Clinical Decisions. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1124-1132.	1.1	52
286	Hypertriglyceridemia Associated With Direct Effects of Olanzapine Rather Than With Weight Gain. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1473-1474.	1.1	16
287	Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. Current issues in clinical implementation. <i>CNS Spectrums</i> , 2006, 11, 8-12.	0.7	7
288	Polymorphic Variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and Dopamine D2 and D3 Receptors and Their Association With Tardive Dyskinesia in Severe Mental Illness. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 448-456.	0.7	92

#	ARTICLE	IF	CITATIONS
289	Nicotine dependence and symptoms in schizophrenia. <i>British Journal of Psychiatry</i> , 2005, 186, 215-221.	1.7	118
290	Suicide attempts and impulsivity. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 152-156.	1.8	167
291	Risperidone Half-Life in a Patient Taking Paroxetine. <i>Pharmacopsychiatry</i> , 2005, 38, 223-225.	1.7	9
292	Benztropine Equivalents for Antimuscarinic Medication. <i>American Journal of Psychiatry</i> , 2005, 162, 627-627.	4.0	27
293	A Brief Measure of High Nicotine Dependence for Busy Clinicians and Large Epidemiological Surveys. <i>Australian and New Zealand Journal of Psychiatry</i> , 2005, 39, 161-168.	1.3	65
294	The Dosing of Atypical Antipsychotics. <i>Psychosomatics</i> , 2005, 46, 262-273.	2.5	111
295	High vulnerability to acute dystonic reactions: A case of antipsychotic exposure and uncontrolled seizure activity. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 770-774.	2.5	7
296	A pilot genetic study of the continuum between compulsivity and impulsivity in females: The serotonin transporter promoter polymorphism. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 713-717.	2.5	51
297	Does clozapine decrease smoking?. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 757-762.	2.5	40
298	Comparison of the Heavy Smoking Index and of the Fagerstrom Test for Nicotine Dependence in a sample of 749 cigarette smokers. <i>Addictive Behaviors</i> , 2005, 30, 1474-1477.	1.7	102
299	Plasma clozapine concentration coefficients of variation in a long-term study. <i>Schizophrenia Research</i> , 2005, 72, 131-135.	1.1	54
300	Suicidal behavior in schizophrenia and depression: a comparison. <i>Schizophrenia Research</i> , 2005, 75, 77-81.	1.1	41
301	Smoking initiation and schizophrenia: a replication study in a Spanish sample. <i>Schizophrenia Research</i> , 2005, 76, 113-118.	1.1	39
302	A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. <i>Schizophrenia Research</i> , 2005, 76, 135-157.	1.1	1,068
303	The CYP2D6 Poor Metabolizer Phenotype May Be Associated With Risperidone Adverse Drug Reactions and Discontinuation. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 15-27.	1.1	265
304	Obesity and Associated Complications in Patients With Severe Mental Illnesses. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 167-173.	1.1	114
305	Cholesterol and Lithium Levels Were Correlated but Serum HDL and Total Cholesterol Levels Were Not Associated With Current Mood State in Bipolar Patients. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 399-400.	1.1	7
306	Variables Associated With Alcohol, Drug, and Daily Smoking Cessation in Patients With Severe Mental Illnesses. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1447-1455.	1.1	40

#	ARTICLE	IF	CITATIONS
307	Psychopharmacology: Atypical Antipsychotic Dosing: The Effect of Smoking and Caffeine. <i>Psychiatric Services</i> , 2004, 55, 491-493.	1.1	98
308	Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004, 254, 318-325.	1.8	20
309	Premenstrual symptoms and luteal suicide attempts. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004, 254, 326-329.	1.8	30
310	New GABAA receptor alpha5 subunit gene polymorphism that may confound genotyping. <i>American Journal of Medical Genetics Part A</i> , 2004, 129B, 27-28.	2.4	2
311	Cytochrome P450 2D6 and antidepressant toxicity and response: what is the evidence?. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 373-375.	2.3	16
312	Toxicity of Dipyridyl Compounds and Related Compounds. <i>Critical Reviews in Toxicology</i> , 2004, 34, 447-460.	1.9	41
313	Lack of association between polymorphic variations in the $\alpha 3$ subunit GABA receptor gene (<i>GABRA3</i>) and suicide attempts. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2004, 28, 409-412.	2.5	11
314	Lack of association between the serotonin transporter promoter gene polymorphism and impulsivity or aggressive behavior among suicide attempters and healthy volunteers. <i>Psychiatry Research</i> , 2004, 126, 99-106.	1.7	50
315	Haloperidol Half-life After Chronic Dosing. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 656-660.	0.7	31
316	Postmortem Clozapine Levels. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 100-101.	0.7	8
317	Psychopharmacology: Atypical Antipsychotic Dosing: The Effect of Co-medication With Anticonvulsants. <i>Psychiatric Services</i> , 2004, 55, 125-128.	1.1	33
318	Variables Associated With Hospitalization Decisions by Emergency Psychiatrists After a Patient's Suicide Attempt. <i>Psychiatric Services</i> , 2004, 55, 792-797.	1.1	71
319	Caffeine Intake in Outpatients With Schizophrenia. <i>Schizophrenia Bulletin</i> , 2004, 30, 935-945.	2.3	41
320	Lack of Association Between Plasma Apolipoprotein E and Suicide Attempts. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 580.	1.1	4
321	Dosing Differences Between Valproic Acid Concentrate and Divalproex Sodium. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 724-725.	1.1	10
322	Variables Associated With High Olanzapine Dosing in a State Hospital. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 1138-1143.	1.1	19
323	Respiratory Infections Rather Than Antibiotics May Increase Clozapine Levels. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 1044-1045.	1.1	23
324	Respiratory infections rather than antibiotics may increase clozapine levels: a critical review of the literature. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 1144-5.	1.1	15

#	ARTICLE	IF	CITATIONS
325	Polydipsia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2003, 253, 37-39.	1.8	59
326	Dimensions of suicidal behavior according to patient reports. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2003, 253, 197-202.	1.8	46
327	A pilot study on a gene-hormone interaction in female suicide attempts. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2003, 253, 281-285.	1.8	18
328	Schizophrenia and tobacco smoking in a Spanish psychiatric hospital. <i>Schizophrenia Research</i> , 2003, 60, 313-317.	1.1	32
329	A pilot study of plasma caffeine concentrations in a US sample of smoker and nonsmoker volunteers. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 165-171.	2.5	68
330	Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 1059-1063.	2.5	93
331	Exploring brief measures of nicotine dependence for epidemiological surveys. <i>Addictive Behaviors</i> , 2003, 28, 1481-1486.	1.7	87
332	Comparison of Two CYP2D6 Genotyping Methods and Assessment of Genotype-Phenotype Relationships. <i>Clinical Chemistry</i> , 2003, 49, 542-551.	1.5	130
333	Glucuronidation enzymes, genes and psychiatry. <i>International Journal of Neuropsychopharmacology</i> , 2003, 6, 57-72.	1.0	99
334	Adverse Drug Reactions to Oxycodone and Hydrocodone in CYP2D6 Ultrarapid Metabolizers. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 420-421.	0.7	71
335	Plasma Cotinine, 3- β -Hydroxycotinine, and Their Glucuronides in White and Black Smokers. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 209-211.	0.7	3
336	Serum Antimuscarinic Activity During Clozapine Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 336-341.	0.7	42
337	Association Between the Menses and Suicide Attempts: A Replication Study. <i>Psychosomatic Medicine</i> , 2003, 65, 237-244.	1.3	34
338	¿Cuál es la seguridad de las medicaciones psiquiátricas después de una sobredosis voluntaria?. <i>European Psychiatry (Ed Española)</i> , 2003, 10, 296-300.	0.0	0
339	Total Cotinine in Plasma: A Stable Biomarker for Exposure to Tobacco Smoke. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 496-501.	0.7	42
340	Schizophrenia and tobacco smoking: a replication study in another US psychiatric hospital. <i>Schizophrenia Research</i> , 2002, 56, 55-65.	1.1	86
341	Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders. <i>Schizophrenia Research</i> , 2002, 56, 47-54.	1.1	149
342	Polydipsia and schizophrenia in a psychiatric hospital: a replication study. <i>Schizophrenia Research</i> , 2002, 57, 293-301.	1.1	54

#	ARTICLE	IF	CITATIONS
343	Schizophrenia and tobacco smoking in a Spanish psychiatric hospital. <i>Schizophrenia Research</i> , 2002, 58, 323-327.	1.1	13
344	How safe are psychiatric medications after a voluntary overdose?. <i>European Psychiatry</i> , 2002, 17, 466-470.	0.1	16
345	A Gender-Specific Association between the Serotonin Transporter Gene and Suicide Attempts. <i>Neuropsychopharmacology</i> , 2002, 26, 692-695.	2.8	61
346	Smoking in Bipolar and Schizophrenic Patients. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 368-369.	1.1	6
347	The Association Between High Nicotine Dependence and Severe Mental Illness May Be Consistent Across Countries. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 812-816.	1.1	116
348	Excessive Antipsychotic Dosing in 2 U.S. State Hospitals. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 998-1003.	1.1	44
349	Pharmacogenomic testing: the cost factor. <i>Pharmacogenomics Journal</i> , 2001, 1, 171-174.	0.9	29
350	Influence of Psychiatric Diagnoses on the Relationship between Suicide Attempts and the Menstrual Cycle. <i>Psychosomatic Medicine</i> , 2001, 63, 509-510.	1.3	3
351	A Prospective Study of the Paradoxical Relationship Between Impulsivity and Lethality of Suicide Attempts. <i>Journal of Clinical Psychiatry</i> , 2001, 62, 560-564.	1.1	136
352	Suicide Attempts in Bipolar Patients. <i>Journal of Clinical Psychiatry</i> , 2001, 62, 963-966.	1.1	126
353	The High Cost of Care. <i>Psychiatric Services</i> , 2000, 51, 676-676.	1.1	0
354	The Relationship Between Menstrual Cycle Phases and Suicide Attempts. <i>Psychosomatic Medicine</i> , 2000, 62, 50-60.	1.3	44
355	A simple high performance liquid chromatographic method for the quantification of total cotinine, total 3- α -hydroxycotinine and caffeine in the plasma of smokers. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2000, 23, 543-549.	1.4	46
356	FC12.05 Smoking in schizophrenia: Prevalence and associated features. <i>European Psychiatry</i> , 2000, 15, 306s-306s.	0.1	0
357	551. Suicide attempts, impulsivity, and low serum cholesterol levels in male patients. <i>Biological Psychiatry</i> , 2000, 47, S168.	0.7	0
358	Extension of a Pilot Study: Impact From the Cytochrome P450 2D6 Polymorphism on Outcome and Costs Associated With Severe Mental Illness. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 246-251.	0.7	194
359	Diurnal Variability of Orofacial Dyskinetic Movements. <i>Pharmacopsychiatry</i> , 1999, 32, 73-75.	1.7	15
360	Economic Grand Rounds: The High Costs of Care for Four Patients With Mania Who Were Not Compliant With Treatment. <i>Psychiatric Services</i> , 1999, 50, 1539-1542.	1.1	16

#	ARTICLE	IF	CITATIONS
361	Possible Interaction Between Warfarin and Quetiapine. <i>Journal of Clinical Psychopharmacology</i> , 1999, 19, 382-383.	0.7	15
362	Double-Blind Study of Clozapine Dose Response in Chronic Schizophrenia. <i>American Journal of Psychiatry</i> , 1999, 156, 1744-1750.	4.0	73
363	A Pilot Study on Risperidone Metabolism. <i>Journal of Clinical Psychiatry</i> , 1999, 60, 469-476.	1.1	117
364	Adding Other Antipsychotics to Clozapine. <i>Journal of Clinical Psychiatry</i> , 1999, 60, 710.	1.1	16
365	A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. <i>Journal of Clinical Psychiatry</i> , 1999, 60, 469-76.	1.1	28
366	First episode in bipolar disorder: misdiagnosis and psychotic symptoms. <i>Journal of Affective Disorders</i> , 1998, 50, 41-44.	2.0	80
367	Therapeutic effects of clozapine on tardive dyskinesia. <i>Cognitive and Behavioral Practice</i> , 1998, 5, 123-131.	0.9	11
368	Menstrual cycle and profiles of suicidal behaviour. <i>Acta Psychiatrica Scandinavica</i> , 1998, 97, 32-35.	2.2	30
369	A factor analysis of the Mini-Mental State Examination in schizophrenic disorders. <i>Acta Psychiatrica Scandinavica</i> , 1998, 98, 366-368.	2.2	8
370	159. Cytochrome P450-2D6 (CYP2D6) genotypes in normal controls. <i>Biological Psychiatry</i> , 1998, 43, S47.	0.7	0
371	Pilot Study of the Cytochrome P450-2D6 Genotype in a Psychiatric State Hospital. <i>American Journal of Psychiatry</i> , 1998, 155, 1278-1280.	4.0	72
372	Tobacco Smoking and Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 1998, 59, 225-228.	1.1	110
373	Absence of Changes in Antidiuretic Hormone, Angiotensin II, and Atrial Natriuretic Peptide With Clozapine Treatment of Polydipsia-Hyponatremia. <i>Journal of Clinical Psychiatry</i> , 1998, 59, 415-419.	1.1	8
374	Drs. de Leon and Bork Reply. <i>Journal of Clinical Psychiatry</i> , 1998, 59, 431.	1.1	1
375	Nicotine dependence among schizophrenic inpatients. <i>Schizophrenia Research</i> , 1997, 24, 257.	1.1	1
376	A comparison of polydipsia prevalence among chronic psychiatric patients using three measurement approaches. <i>Biological Psychiatry</i> , 1997, 42, 1097-1104.	0.7	8
377	Interaction of Sertraline With Clozapine. <i>Journal of Clinical Psychopharmacology</i> , 1997, 17, 119-120.	0.7	36
378	Clozapine Withdrawal Resulting in Delirium With Psychosis. <i>Journal of Clinical Psychiatry</i> , 1997, 58, 252-255.	1.1	78

#	ARTICLE	IF	CITATIONS
379	Risperidone and Cytochrome P450 3A. <i>Journal of Clinical Psychiatry</i> , 1997, 58, 450.	1.1	48
380	Neurological frontal signs and neuropsychological deficits in schizophrenic patients. <i>Schizophrenia Research</i> , 1996, 20, 15-20.	1.1	32
381	Repetitive behaviors in schizophrenia: a single disturbance or discrete symptoms?. <i>Schizophrenia Research</i> , 1996, 20, 221-229.	1.1	44
382	Polydipsia and water intoxication in a long-term psychiatric hospital. <i>Biological Psychiatry</i> , 1996, 40, 28-34.	0.7	71
383	Instrumental assessment of longitudinal variations in tardive dyskinesia. <i>Biological Psychiatry</i> , 1996, 39, 548.	0.7	0
384	A study of bedside screening procedures for cognitive deficits in chronic psychiatric inpatients. <i>Comprehensive Psychiatry</i> , 1996, 37, 328-335.	1.5	8
385	Dr. de Leon Replies. <i>American Journal of Psychiatry</i> , 1996, 153, 583-a-584.	4.0	9
386	Diurnal and weekly variation of tardive dyskinesia measured by digital image processing. <i>Psychopharmacology</i> , 1996, 124, 373-376.	1.5	6
387	Smoking and Vulnerability for Schizophrenia. <i>Schizophrenia Bulletin</i> , 1996, 22, 405-409.	2.3	139
388	Problems and Progress in the Diagnosis and Treatment of Polydipsia and Hyponatremia. <i>Schizophrenia Bulletin</i> , 1996, 22, 455-464.	2.3	78
389	Clock Drawing in Schizophrenia. <i>Psychological Reports</i> , 1996, 79, 923-928.	0.9	19
390	Clozapine Levels After Clozapine Discontinuation. <i>Journal of Clinical Psychopharmacology</i> , 1996, 16, 193-194.	0.7	16
391	Clozapine levels and caffeine. <i>Journal of Clinical Psychiatry</i> , 1996, 57, 175-6.	1.1	31
392	Positive and negative symptoms/syndromes in schizophrenia: reliability and validity of different diagnostic systems. <i>Psychological Medicine</i> , 1995, 25, 43-50.	2.7	51
393	Oral tardive dyskinesia: validation of a measuring device using digital image processing. <i>Psychopharmacology</i> , 1995, 117, 162-165.	1.5	7
394	Treatment of Polydipsia and Hyponatremia in Psychiatric Patients. <i>Neuropsychopharmacology</i> , 1995, 12, 133-138.	2.8	60
395	Schizophrenia and smoking: an epidemiological survey in a state hospital. <i>American Journal of Psychiatry</i> , 1995, 152, 453-455.	4.0	377
396	Misidentification Syndromes in Schizophrenia: Case Reviews with Implications for Classification and Prevalence. <i>Australian and New Zealand Journal of Psychiatry</i> , 1995, 29, 63-68.	1.3	20

#	ARTICLE	IF	CITATIONS
397	Osteoporosis and schizophrenia: Can we limit known risk factors?. <i>Biological Psychiatry</i> , 1995, 38, 131-132.	0.7	39
398	Nicotine addiction in chronic schizophrenic inpatients. <i>Biological Psychiatry</i> , 1995, 37, 640.	0.7	6
399	Schizophrenic syndrome and Wisconsin Card Sorting Test dimensions. <i>Psychiatry Research</i> , 1995, 58, 45-51.	1.7	49
400	Does clozapine induce akathisia?. <i>Schizophrenia Research</i> , 1995, 15, 206.	1.1	0
401	Mini-mental state examination and trail making test in schizophrenic inpatients. <i>Schizophrenia Research</i> , 1995, 15, 114.	1.1	0
402	Urine specific gravity may not measure polydipsia in the presence of water retention. <i>Schizophrenia Research</i> , 1995, 15, 138.	1.1	1
403	Polydipsia and water intoxication in psychiatric patients: A review of the epidemiological literature. <i>Biological Psychiatry</i> , 1994, 35, 408-419.	0.7	254
404	An empirical analysis of latent structures underlying schizophrenic symptoms: a four-syndrome model. <i>Biological Psychiatry</i> , 1994, 36, 726-736.	0.7	112
405	Attentional effects on a test of ecological memory in schizophrenia. <i>Biological Psychiatry</i> , 1994, 35, 634.	0.7	0
406	The effects of chronic psychosis on rivermead behavioral memory test performance. <i>Biological Psychiatry</i> , 1994, 35, 637.	0.7	0
407	The stability and agreement of general impairment indicators in schizophrenia. <i>Biological Psychiatry</i> , 1994, 35, 637.	0.7	1
408	Confirmatory factor analysis to test schizophrenic models. <i>Biological Psychiatry</i> , 1994, 35, 695.	0.7	0
409	Epidemiological and clinical factors associated with polydipsia in a state hospital. <i>Biological Psychiatry</i> , 1994, 35, 698-699.	0.7	2
410	Urine concentration of creatinine: Comparison of methods to detect polyuria. <i>Biological Psychiatry</i> , 1994, 35, 702-703.	0.7	1
411	Schizophrenic syndromes associated with treatment response. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1994, 18, 87-99.	2.5	22
412	High Dosages Of Neuroleptics --A survey in a long-term hospital. <i>Neuropsychopharmacology</i> , 1994, 11, 267-267.	2.8	1
413	A Pilot Effort to Determine Benztropine Equivalents of Anticholinergic Medications. <i>Psychiatric Services</i> , 1994, 45, 606-607.	1.1	13
414	Anticholinergics to treat clozapine withdrawal. <i>Journal of Clinical Psychiatry</i> , 1994, 55, 119-20.	1.1	33

#	ARTICLE	IF	CITATIONS
415	Neuroendocrine Factors Influencing Polydipsia in Psychiatric Patients: An Hypothesis. <i>Neuropsychopharmacology</i> , 1993, 9, 157-166.	2.8	59
416	The test-retest reliability of the Mini-Mental State Examination in chronic schizophrenic patients. <i>Acta Psychiatrica Scandinavica</i> , 1993, 88, 188-192.	2.2	18
417	Delusions and Hallucinations in Schizophrenic Patients. <i>Psychopathology</i> , 1993, 26, 286-291.	1.1	8
418	Negative symptoms and emotional blunting in schizophrenic patients. <i>Journal of Clinical Psychiatry</i> , 1993, 54, 103-8.	1.1	10
419	Are There More Than Two Syndromes in Schizophrenia?. <i>British Journal of Psychiatry</i> , 1992, 161, 335-343.	1.7	292
420	Clozapine Treatment of Polydipsia. <i>Journal of Clinical Psychopharmacology</i> , 1992, 12, 218.	0.7	2
421	Positive and negative symptoms in schizophrenia: Where are the data?. <i>Biological Psychiatry</i> , 1992, 31, 431-434.	0.7	21
422	Formal thought disorder in schizophrenia: A factor analytic study. <i>Comprehensive Psychiatry</i> , 1992, 33, 105-110.	1.5	64
423	Positive versus negative schizophrenia and basic symptoms. <i>Comprehensive Psychiatry</i> , 1992, 33, 202-206.	1.5	26
424	Delusion of parasitosis or chronic tactile hallucinosis: Hypothesis about their brain physiopathology. <i>Comprehensive Psychiatry</i> , 1992, 33, 25-33.	1.5	42
425	Premorbid personality and positive and negative symptoms in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 1991, 84, 336-339.	2.2	54
426	Negative symptoms, defect state and Huber's basic symptoms: A comparison of the concepts. <i>Psychiatric Quarterly</i> , 1991, 62, 277-298.	1.1	7
427	Clozapine and jaw dyskinesia: a case report. <i>Journal of Clinical Psychiatry</i> , 1991, 52, 494-5.	1.1	20
428	Neuroleptic-induced catatonia: Neuroleptic malignant syndrome?. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1990, 14, IN5-136.	2.5	3
429	Dysmorphophobia Misdiagnosed as Obsessive-Compulsive Disorder. <i>Psychosomatics</i> , 1990, 31, 220-222.	2.5	43
430	Tyramine and New Monoamine Oxidase Inhibitor Drugs. <i>British Journal of Psychiatry</i> , 1989, 155, 32-37.	1.7	48
431	Dysmorphophobia: Body dysmorphic disorder or delusional disorder, somatic subtype?. <i>Comprehensive Psychiatry</i> , 1989, 30, 457-472.	1.5	61
432	Measurement of negative symptoms in schizophrenia. <i>Psychiatric Developments</i> , 1989, 7, 211-34.	0.2	10

#	ARTICLE	IF	CITATIONS
433	Why do some psychiatric patients somatize?. Acta Psychiatrica Scandinavica, 1987, 76, 203-209.	2.2	24
434	A Brief Measure of High Nicotine Dependence for Busy Clinicians and Large Epidemiological Surveys., O, .		6